Document Detail


S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury.
MedLine Citation:
PMID:  23190274     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
As an astrocytic protein specific to the central nervous system, S100b is a potentially useful marker in outcome prediction after traumatic brain injury (TBI). Some studies have questioned the validity of S100b, citing the extracerebral origins of the protein as reducing the specificity of the marker. This study evaluated S100b as a prognostic biomarker in adult subjects with severe TBI (sTBI) by comparing outcomes with S100b temporal profiles generated from both cerebrospinal fluid (CSF) (n = 138 subjects) and serum (n = 80 subjects) samples across a 6-day time course. Long-bone fracture, Injury Severity Score (ISS), and isolated head injury status were variables used to assess extracerebral sources of S100b in serum. After TBI, CSF and serum S100b levels were increased over healthy controls across the first 6 days post-TBI (p ≤ 0.005 and p ≤ 0.031). Though CSF and serum levels were highly correlated during early time points post-TBI, this association diminished over time. Bivariate analysis showed that subjects who had temporal CSF profiles with higher S100b concentrations had higher acute mortality (p < 0.001) and worse Glasgow Outcome Scale (GOS; p = 0.002) and Disability Rating Scale (DRS) scores (p = 0.039) 6 months post-injury. Possibly as a result of extracerebral sources of S100b in serum, as represented by high ISS scores (p = 0.032), temporal serum profiles were associated with acute mortality (p = 0.015). High CSF S100b levels were observed in women (p = 0.022) and older subjects (p = 0.004). Multivariate logistic regression confirmed CSF S100b profiles in predicting GOS and DRS and showed mean and peak serum S100b as acute mortality predictors after sTBI.
Authors:
Akash Goyal; Michelle D Failla; Christian Niyonkuru; Krutika Amin; Anthony Fabio; Rachel P Berger; Amy K Wagner
Related Documents :
1405324 - Angiotensin ii does not increase renal prostaglandin e2 in response to pressure reduction.
9524054 - Plasminogen activator inhibitor-1 and angiotensin i converting enzyme gene polymorphism...
10610744 - Clinical implications of increased plasma angiotensin ii despite ace inhibitor therapy ...
7621674 - Concentration of chicken gonadotropin-releasing hormones i and ii in microdissected are...
7589174 - Corticotropin-releasing factor inhibits antigen-induced plasma extravasation in airways.
23317804 - Female sex hormones and cytokine secretion in women with multiple sclerosis.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of neurotrauma     Volume:  30     ISSN:  1557-9042     ISO Abbreviation:  J. Neurotrauma     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-06-19     Completed Date:  2014-01-23     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  8811626     Medline TA:  J Neurotrauma     Country:  United States    
Other Details:
Languages:  eng     Pagination:  946-57     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Biological Markers / blood*,  cerebrospinal fluid*
Brain Injuries / blood*,  cerebrospinal fluid*,  mortality
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Female
Glasgow Outcome Scale
Humans
Male
Prognosis
S100 Calcium Binding Protein beta Subunit / blood*,  cerebrospinal fluid*
Grant Support
ID/Acronym/Agency:
R49/CCR323155//PHS HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/S100 Calcium Binding Protein beta Subunit; 0/S100B protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of cross-sectional root canal shape on filled canal volume and remaining root filling materia...
Next Document:  Latest treatment for lower urinary tract dysfunction: Therapeutic agents and mechanism of action.